[go: up one dir, main page]

WO2009134057A3 - 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제 - Google Patents

안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제 Download PDF

Info

Publication number
WO2009134057A3
WO2009134057A3 PCT/KR2009/002225 KR2009002225W WO2009134057A3 WO 2009134057 A3 WO2009134057 A3 WO 2009134057A3 KR 2009002225 W KR2009002225 W KR 2009002225W WO 2009134057 A3 WO2009134057 A3 WO 2009134057A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulation
receptor blocker
active ingredient
release compartment
angiotensin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/002225
Other languages
English (en)
French (fr)
Other versions
WO2009134057A2 (ko
Inventor
김성욱
전성수
조영관
구자성
이아람
손재운
김정택
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanall Pharmaceutical Co Ltd
Original Assignee
Hanall Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Pharmaceutical Co Ltd filed Critical Hanall Pharmaceutical Co Ltd
Priority to US12/990,400 priority Critical patent/US20110117194A1/en
Priority to EP09738963A priority patent/EP2281557A4/en
Priority to CN2009801233256A priority patent/CN102065847A/zh
Publication of WO2009134057A2 publication Critical patent/WO2009134057A2/ko
Publication of WO2009134057A3 publication Critical patent/WO2009134057A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 약리학적 활성성분인 안지오텐신-Ⅱ-수용체 차단제 및 방출제어물질을 포함하는 약제학적 제제와 약리학적 활성성분으로 간염 예방 및 억제제를 포함하는 선방출성 구획, 및 약리학적 활성성분으로 안지오텐신-Ⅱ-수용체 차단제를 포함하는 지연방출성 구획을 포함하는 약제학적 제제를 제공한다. 본 발명의 제제는 복용시 약리학적 및 임상학적 항압효과와 합병증 예방 효과를 극대화하고, 간에서 동일한 효소에 의해 대사되는 약물과의 상호작용을 피할 수 있으며, 장기간 투여로 인한 약물성 간염 발병을 예방 및 억제할 수 있다.
PCT/KR2009/002225 2008-04-29 2009-04-28 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제 Ceased WO2009134057A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/990,400 US20110117194A1 (en) 2008-04-29 2009-04-28 Pharmaceutical formulation containing angiotensin-ii receptor blocker
EP09738963A EP2281557A4 (en) 2008-04-29 2009-04-28 PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
CN2009801233256A CN102065847A (zh) 2008-04-29 2009-04-28 含有血管紧张素-ⅱ受体阻断剂的药物制剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0040002 2008-04-29
KR20080040002 2008-04-29

Publications (2)

Publication Number Publication Date
WO2009134057A2 WO2009134057A2 (ko) 2009-11-05
WO2009134057A3 true WO2009134057A3 (ko) 2010-01-21

Family

ID=41255547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/002225 Ceased WO2009134057A2 (ko) 2008-04-29 2009-04-28 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제

Country Status (5)

Country Link
US (1) US20110117194A1 (ko)
EP (1) EP2281557A4 (ko)
KR (2) KR101209319B1 (ko)
CN (1) CN102065847A (ko)
WO (1) WO2009134057A2 (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
US20120251588A1 (en) * 2011-03-30 2012-10-04 Miyuki Fukasawa Coating Composition, Solid Preparation Coated Therewith, and Method for Preparing Solid Preparation
CN103083367B (zh) * 2011-11-01 2015-05-20 上海交通大学医学院附属第三人民医院 一种氯沙坦银杏叶复方制剂及其制备方法
WO2013100876A1 (en) * 2011-12-27 2013-07-04 Mahmut Bilgic Risperidone formulations
WO2014068507A1 (en) * 2012-11-02 2014-05-08 Abbott Healthcare Pvt. Ltd. Solid oral pharmaceutical compositions of telmisartan, essentially free of surfactants
CN102895185B (zh) * 2012-11-05 2015-03-25 西安德天药业股份有限公司 一种联苯双酯速释微丸及其制备方法和应用
JP6428340B2 (ja) * 2014-05-23 2018-11-28 ニプロ株式会社 テルミサルタンを含む医薬組成物の造粒方法
CN105106963B (zh) * 2014-09-24 2018-02-27 国药集团德众（佛山）药业有限公司 马来酸曲美布汀缓释制剂及其制备方法
US20180071272A1 (en) * 2014-10-23 2018-03-15 The Trustees Of The University Of Pennsylvania Novel chronotherapy based on circadian rhythms
CN104523658B (zh) * 2014-12-11 2017-02-22 陈长潭 一种厄多司坦吸入粉雾剂及其制备方法
CN106236726B (zh) * 2015-06-12 2018-03-20 湖南中南制药有限责任公司 奥拉米特包衣缓释片及其制备方法
JP7189127B2 (ja) * 2016-09-06 2022-12-13 メタボリック・テクノロジーズ，インコーポレーテッド 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法
KR102647471B1 (ko) * 2016-10-10 2024-03-14 한미약품 주식회사 고미 및 이물감이 개선된 에르도스테인 과립제제
US11040007B2 (en) 2017-01-24 2021-06-22 Woosung Pharmaceutical Co., Ltd. Injection composition containing acetaminophen
KR101920628B1 (ko) * 2017-04-12 2018-11-22 대원제약주식회사 안지오텐신 수용체 길항제를 포함하는 약제학적 조성물
CN109169638A (zh) * 2018-11-12 2019-01-11 苏州瑞徕生物科技有限公司 一种细胞保存液及其用途
CN109350604B (zh) * 2018-11-20 2020-04-21 广州迈达康医药科技有限公司 一种替米沙坦肠溶片及其制备方法
CN113164396B (zh) 2018-11-26 2023-11-03 宝洁公司 含有硫辛酸的固体药物制剂及其用途
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
KR102304910B1 (ko) * 2021-01-11 2021-09-27 알리코제약(주) 칸데사르탄을 함유하는 안정한 약학적 조성물
CN112691115A (zh) * 2021-02-01 2021-04-23 上海赛普瑞特生物科技有限公司 预防/治疗胃肠粘膜和肝脏损伤的阿拉伯木聚糖及复合物
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
CN113713110B (zh) * 2021-09-22 2022-11-15 滨州医学院 一种药物组合物及其应用
CN115025048B (zh) * 2022-07-28 2023-12-15 上海智同医药科技有限公司 一种阿瑞匹坦的三元固体分散体
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR20070078625A (ko) * 2006-01-27 2007-08-01 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
KR20080018841A (ko) * 2006-08-24 2008-02-28 한올제약주식회사 방출성이 제어된 디히드로피리딘계 칼슘길항제/스타틴계지질저하제의 복합제제
KR20080032616A (ko) * 2006-10-10 2008-04-15 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU696868B2 (en) 1994-03-29 1998-09-17 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
SK283348B6 (sk) 1996-04-05 2003-06-03 Takeda Chemical Industries, Ltd. Farmaceutický prípravok obsahujúci zlúčeninu s antagonickým účinkom na angiotenzín II
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
KR20010086245A (ko) * 1998-03-04 2001-09-10 다케다 야쿠힌 고교 가부시키가이샤 Ａⅱ 길항제용 서방성 제제, 그것의 제조 및 용도
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US7413751B2 (en) 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
SI1587584T1 (sl) 2003-01-16 2007-10-31 Boehringer Ingelheim Int Farmacevtska kombinacija za profilakso ali terapijo kardiovaskularnih, kardiopulmonalnih, pulmonalnih ali renalnih bolezni
US20060078615A1 (en) 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
EP2210595A1 (en) * 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR20070078625A (ko) * 2006-01-27 2007-08-01 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
KR20080018841A (ko) * 2006-08-24 2008-02-28 한올제약주식회사 방출성이 제어된 디히드로피리딘계 칼슘길항제/스타틴계지질저하제의 복합제제
KR20080032616A (ko) * 2006-10-10 2008-04-15 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제

Also Published As

Publication number Publication date
KR101241624B1 (ko) 2013-03-11
KR20110103928A (ko) 2011-09-21
CN102065847A (zh) 2011-05-18
WO2009134057A2 (ko) 2009-11-05
KR101209319B1 (ko) 2012-12-06
KR20090114314A (ko) 2009-11-03
US20110117194A1 (en) 2011-05-19
EP2281557A4 (en) 2011-08-31
EP2281557A2 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
WO2009134057A3 (ko) 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
WO2010008203A3 (ko) 칼슘채널길항제를 포함하는 약제학적 제제
US20240409514A1 (en) Methods for inhibiting native and promiscuous uptake of monoamine neurotransmitters
WO2009127922A3 (ko) 심혈관계 질환 치료용 약제학적 제제
TN2009000317A1 (en) Solid preparation comprising alogliptin and pioglitazone
CL2008000823A1 (es) Formulacion farmaceutica de liberacion inmediata que comprende dapagliflozina propilenglicol hidrato y un portador farmaceuticamente aceptable; uso para tratar diabetes, intolerancia a la glucosa, resistencia a la insulina, entre otras.
WO2008069941A3 (en) Modified release ibuprofen solid oral dosage form
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
WO2009054423A1 (ja) オキサジアゾリジンジオン化合物
WO2010066749A3 (en) Ulipristal acetate tablets
WO2009125981A3 (ko) 약제학적 제제
WO2010045656A3 (en) Novel sglt2 inhibitor dosage forms
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
WO2007048219A3 (en) Sustained drug release composition
TW200833372A (en) Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound
WO2009059701A3 (de) Retardtabletten mit hydromorphon
WO2011029948A3 (de) Transdermales therapeutisches system zur verabreichung von fentanyl oder einem analogstoff davon
WO2007143163A3 (en) Pharmaceutical compositions for sustained release of phenyephrine
AR066924A1 (es) Formulacion de nevirapina de liberacion prolongada
MX2010007281A (es) Composiciones farmaceuticas de amlodipina y valsartan.
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
TR201001903A2 (tr) Uzatılmış salımlı tiyokolşiklozit tablet.
WO2010044581A3 (ko) N1-벤조[1,3]다이옥솔-5-일메틸-n2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물
WO2007146068A3 (en) Controlled release alfuzosin hydrochloride formulation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980123325.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09738963

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009738963

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12990400

Country of ref document: US